PL3578201T3 - Metody i kompozycje dla naturalnych komórek cytotoksycznych - Google Patents

Metody i kompozycje dla naturalnych komórek cytotoksycznych

Info

Publication number
PL3578201T3
PL3578201T3 PL19175670.9T PL19175670T PL3578201T3 PL 3578201 T3 PL3578201 T3 PL 3578201T3 PL 19175670 T PL19175670 T PL 19175670T PL 3578201 T3 PL3578201 T3 PL 3578201T3
Authority
PL
Poland
Prior art keywords
compositions
methods
cytotoxic cells
natural cytotoxic
natural
Prior art date
Application number
PL19175670.9T
Other languages
English (en)
Inventor
Alicja COPIK
Vijay Reddy
Jeremiah OYER
Original Assignee
University Of Central Florida Research Foundation Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Central Florida Research Foundation Incorporated filed Critical University Of Central Florida Research Foundation Incorporated
Publication of PL3578201T3 publication Critical patent/PL3578201T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL19175670.9T 2012-06-28 2013-06-28 Metody i kompozycje dla naturalnych komórek cytotoksycznych PL3578201T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261665591P 2012-06-28 2012-06-28

Publications (1)

Publication Number Publication Date
PL3578201T3 true PL3578201T3 (pl) 2023-09-11

Family

ID=49783918

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19175670.9T PL3578201T3 (pl) 2012-06-28 2013-06-28 Metody i kompozycje dla naturalnych komórek cytotoksycznych

Country Status (16)

Country Link
US (5) US9623082B2 (pl)
EP (3) EP4279579A3 (pl)
AU (4) AU2013282353B2 (pl)
CA (1) CA2877968A1 (pl)
DK (1) DK3578201T3 (pl)
ES (1) ES2943932T3 (pl)
FI (1) FI3578201T3 (pl)
HR (1) HRP20230424T1 (pl)
HU (1) HUE061931T2 (pl)
LT (1) LT3578201T (pl)
PL (1) PL3578201T3 (pl)
PT (1) PT3578201T (pl)
RS (1) RS64172B1 (pl)
SG (2) SG10201610915XA (pl)
SI (1) SI3578201T1 (pl)
WO (1) WO2014005072A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
BR112017008696A2 (pt) 2014-10-27 2017-12-26 Univ Central Florida Res Found Inc métodos e composições para células exterminadoras naturais
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
KR102650803B1 (ko) * 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
US11696927B2 (en) * 2017-02-28 2023-07-11 University Of Central Florida Research Foundation, Inc. PM21 particles to improve bone marrow homing of NK cells
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019024656A2 (pt) * 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
FI3755347T3 (fi) * 2018-02-21 2025-07-29 Univ Texas Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CN109627342B (zh) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 应用于nk细胞培养的蛋白质、培养基配方组合及制备方法
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
JP7683932B2 (ja) * 2019-01-24 2025-05-27 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞を刺激するための組成物及び方法
EP3917528A4 (en) * 2019-01-28 2022-12-28 University of Rhode Island Board of Trustees Phlip® targeted delivery of potent cytotoxic compounds
US20200246420A1 (en) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education pHLIP® peptide-mediated epitope tethering at cell surfaces
AU2020221311A1 (en) * 2019-02-14 2021-10-07 Research Institute At Nationwide Children's Hospital Use of plasma membrane particles, liposomes, and exosomes to assay immune cell potency
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
KR20220026575A (ko) * 2019-06-25 2022-03-04 시티 오브 호프 Pdl1 양성 nk 세포 암 치료
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
EP3914699A4 (en) * 2019-12-09 2023-03-29 ImmunityBio, Inc. SCREENING OF CELL CLONES EXPRESSING POLYGENIC TRANSGENES BY NON-ANTIBIOTIC DEPENDENT POSITIVE SELECTION
MX2022008415A (es) 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
US20250339502A1 (en) * 2020-03-20 2025-11-06 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
EP4163367A4 (en) * 2020-06-09 2024-06-26 Samsung Life Public Welfare Foundation GENETICALLY MANIPULATED CELL STRAIN FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
US20240141295A1 (en) 2020-08-31 2024-05-02 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
US20240299542A1 (en) 2021-01-05 2024-09-12 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
KR20240036997A (ko) * 2022-09-14 2024-03-21 재단법인 한국마이크로의료로봇연구원 사이토카인 활성 강화된 자연살해세포 유래 엑소좀의 암 치료용 생물학적 조성물 및 이의 용도
CN117987365B (zh) * 2023-12-27 2024-08-06 常州市第一人民医院 一种裂亡前列腺癌细胞囊泡的工程化改造方法及其应用
WO2026050706A1 (en) 2024-08-30 2026-03-05 Aventis Inc. Nk cells having reduced cd38 expression and method for producing
WO2026068686A1 (en) 2024-09-27 2026-04-02 Kiadis Pharma Intellectual Property B.V. Methods of enhancing plasma membrane particle functionality and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
WO2000067761A1 (en) 1999-05-06 2000-11-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
DE60138222D1 (de) * 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
WO2002097038A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
CN1893925B (zh) * 2003-08-21 2011-04-27 利普泰克有限公司 树突细胞的体内靶向
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005070120A2 (en) * 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
US7592313B2 (en) * 2004-05-17 2009-09-22 Board Of Trustees Of The University Of Illinois Method of stimulating proliferation of regulatory T cells in a diabetic mammal
EP1809738B1 (en) * 2004-11-02 2014-03-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for treating hyperproliferative disorders
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
EP2805971A1 (en) * 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21 antagonists
JP2009518427A (ja) * 2005-12-08 2009-05-07 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド Ｉｎｖｉｖｏ細胞表面操作
DK2222706T4 (en) * 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
WO2010071836A1 (en) * 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013175237A1 (en) 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent

Also Published As

Publication number Publication date
EP3578201B1 (en) 2023-04-19
AU2021202439B2 (en) 2024-09-05
PT3578201T (pt) 2023-05-10
EP4279579A2 (en) 2023-11-22
US9623082B2 (en) 2017-04-18
AU2021202439A1 (en) 2021-05-13
ES2943932T3 (es) 2023-06-16
US20200138908A1 (en) 2020-05-07
AU2013282353B2 (en) 2018-10-25
AU2024267081A1 (en) 2024-12-19
SI3578201T1 (sl) 2023-06-30
US20190117736A1 (en) 2019-04-25
US20150190471A1 (en) 2015-07-09
EP3578201A1 (en) 2019-12-11
US20170319659A1 (en) 2017-11-09
AU2019200525A1 (en) 2019-02-14
FI3578201T3 (fi) 2023-05-05
EP2866834A1 (en) 2015-05-06
LT3578201T (lt) 2023-05-25
US10463715B2 (en) 2019-11-05
SG10201610915XA (en) 2017-02-27
SG11201408697QA (en) 2015-02-27
DK3578201T3 (da) 2023-05-08
US11617781B2 (en) 2023-04-04
EP2866834A4 (en) 2015-12-09
HRP20230424T1 (hr) 2023-07-07
EP4279579A3 (en) 2024-02-21
AU2013282353A1 (en) 2015-02-12
US20230321191A1 (en) 2023-10-12
HUE061931T2 (hu) 2023-09-28
WO2014005072A1 (en) 2014-01-03
US10874715B2 (en) 2020-12-29
CA2877968A1 (en) 2014-01-03
EP2866834B1 (en) 2019-05-22
AU2019200525B2 (en) 2021-01-21
RS64172B1 (sr) 2023-05-31
US12280094B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
IL264271A (en) Methods of generating natural killer cells
PT3578201T (pt) Métodos e composições para células assassinas naturais
PL2884999T3 (pl) Sposób i kompozycje do immunoterapii komórkowej
IL267283A (en) Methods and preparations for producing epicardial cells
IL242273B (en) Methods and compositions for enhancing cd4+ regulatory t cells
SI2978419T1 (sl) Sestavki za izboljšanje viabilnosti celic in postopki njihove uporabe
PL2734049T3 (pl) Kompozycje probiotyczne i sposoby
CL2014003386A1 (es) Métodos y composiciones para producción de biometano
EP3488847C0 (en) SEMIFLUORINATED ALKANE COMPOSITIONS
HRP20181448T1 (hr) Antihelmintski spojevi i sastavi te postupak za njihovu uporabu
EP2850187A4 (en) COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2943591A4 (en) METHOD AND COMPOSITIONS FOR PROFILING SINGLE CELL EXPRESSION
IL229176A0 (en) Preparations of living cells and their uses
EP2758183A4 (en) BIODEGRADABLE COMPOSITIONS AND THEIR USE
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
ZA201406726B (en) Methods and composition related to brown adipose-like cells
GB201200458D0 (en) Methods of preparing cells and compositions
ME03029B (me) Kompozicije koje obuhvataju vortioksetin i donepezil
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
EP2735581A4 (en) COMPOSITION AND POLYMER
BR112013033137A2 (pt) composições e soluções de glicerol
EP2932536A4 (en) COMPOSITIONS AND METHODS FOR ENHANCED SOLAR CELLS
DK2935530T3 (da) Fischer-tropsch-afledte brændstofsammensætninger